AMI finds new partner for Feridex

Article

Advanced Magnetics this month announced a licensing deal with Berlex Laboratories for Feridex,AMI's MR contrast agent for detecting primary and metastatic livertumors. The deal completes a slick piece of horse-trading forAdvanced Magnetics, which

Advanced Magnetics this month announced a licensing deal with Berlex Laboratories for Feridex,AMI's MR contrast agent for detecting primary and metastatic livertumors. The deal completes a slick piece of horse-trading forAdvanced Magnetics, which reacquired Feridex from Sterling Winthroplast year after that company's diagnostic imaging business waspurchased by Hafslund Nycomed.

Advanced Magnetics, of Cambridge, MA, initially licensed rightsto Feridex to Sterling Winthrop in 1993, and AMI received $3.5million in licensing fees from Sterling. A clause in the contractstated that the agreement was not transferable to another party,however, and AMI president Jerome Goldstein exercised that clauselast year after Sterling Winthrop was purchased by Nycomed (SCAN10/26/94 and 8/31/94).

Under the Berlex deal, Advanced Magnetics has received a $5million licensing fee from Berlex in exchange for exclusive marketingrights in the U.S. and Canada. Berlex will pay an additional $5million when Feridex is approved for marketing by the Food andDrug Administration. AMI will also receive payments for manufacturingFeridex as well as a royalty on sales.

AMI filed a new drug application (NDA) with the FDA for Feridexin February 1994. The product has been approved in Europe andwas launched this month by AMI's European marketing partner, Guerbetof France.

Advanced Magnetics also announced a cross-licensing agreementwith Berlex parent Schering AG. The deal gives both parties aworldwide license under each other's patents to their respectivesuperparamagnetic contrast agents.

Recent Videos
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Related Content
© 2025 MJH Life Sciences

All rights reserved.